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Attenuated Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only 
currently available vaccine against tuberculosis. It is highly effective in pre-
exposure immunisation against TB in children when administered by 
subcutaneous route to newborns. However, it does not provide permanent 
protection  in adults.  
 
In this work, polymeric chitosan-alginate microparticles have been evaluated 
as potential nasal delivery systems and mucosal adjuvants for live attenuated 
BCG.  
 
Chitosan (CS) has been employed as adjuvant and mucosal permeation-
enhancer, and, together with alginate (ALG), as additive to enhance BCG-
loaded microparticles (MPs) cellular uptake in a human monocyte cell line, by 
particle surface modification. The most suitable particles were used for vaccine 
formulation and evaluation of immune response following intranasal 
immunisation of BALB/c mice. 
Microparticles production: 
• CS/ALG-BCG MPs were produced by by ionotropic gelation.1  
• BCG (*) and TPP were dispersed in 0.1 % (w/v) CS (Sigma-Aldrich) solution, 
followed by 0.1 % (w/v) ALG (FMC BioPolymer) solution.2 
(*) M. Bovis BCG Pasteur (ATCC35734) and a recombinant M. Bovis BCG expressing Green Fluorescent 
Protein (GFP) were used.3 
Characterization methods:  
• Particle size  laser diffraction (Mastersizer2000, Malvern).  
• Zeta potential   electrophoretic mobility (Malvern Zetasizer).  
• Cell uptake  rBCG-loaded MPs were incubated in THP-1 cell cultures for 24h. 
Cells were observed under fluorescence microscopy. Multiplicity of Infection 
(MOI) = n rBCG cells /n THP-1 cells .4 
Immunisation studies: 
• Four groups of female BALB/c (n=4/group), 6-8 weeks old, were immunized 
with 1x107 BCG Pasteur cells by subcutaneous or intranasal administration.  
• Specific IgG, IgG2a, IgG1 were determined using purified protein derivative 
(PPD) bovine tuberculin. 
References 
[1] Calvo et al (1997) J Appl Polym Sci. 63:125–32. 
[2] Caetano at al (2012) Bioengineering. IEEE 2nd Portuguese Meeting, pp. 1-3. 
[3] Jordão et al (2008) Cellular Microbiology 10: 529-548. 
[4] Bettencourt et al (2010) Infection. 614–621. 
Acknowledgments 
Prof. Elsa Anes, Dr. David Pires and Dr. Nuno Carmo (FFUL) for BCG strains supply and 
practical support. FCT, Portugal (PEst-OE/SAU/UI4013/2011) for financial support.  
Figure 2. Fluorescence microscopy images from THP-1 cells after 24h of 
incubation with: (a) plain rBCG; (b) rBCG-CS; (c) rBCG-CS/ALG MPs. GFP-
expressing bacteria (green), Lysotrack labeled lysosomal compartments (red) and 
DAPI stained nuclei (blue). 
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THP-1 cell uptake 
rBCG-loaded CS/ALG MPS were uptaken by THP1 cells. As expected, due to ZP, 
and surface area, monodispersed bacteria were more extensively internalized 
(MOI=10) than clumped bacteria (MOI=1).  
INTRODUCTION METHODS 
RESULTS AND DISCUSSION 
The developed particulate system allowed efficient whole live bacterial microencapsulation. BCG-loaded CS/ALG microparticles were 
efficiently uptaken by a human monocyte cell line, and improved Th1 cellular immune response in mice, as well as mucosal 
immunity. Thus CS/ALG MPs exhibit promising features potential as BCG vaccine carrier for mucosal immunisation.  
CONCLUSIONS 
Particle Size and Surface charge 
CS/ALG MPs presented a size of 10.0–11.8 µm in diameter with narrow size 
distribution and zeta potential (ZP) ranging from -23.7 ± 0.2 to +12.1 ± 0.9 mV. 
In both cases, particles were spherical and non-aggregated. CS:ALG ratio 1:1 
(L14) was chosen for BCG microencapsulation. 
Table 1. Particle size distribution and zeta potential of CS/ALG microparticles. 
BCG-loaded MPS presented 22.2 µm in 
diameter, negative ZP (-14.4 ± 2.1 mV), 
and good encapsulation efficiency (64% ).   
 
BCG modification with CS turned ZP 
strongly to positive values (-23.1 mV to 
+90.6 mV). This could enhance 
microparticle uptake by THP-1 cells.  
Figure 1. Mean diameter, ZP and morphology of  
BCG-loaded  MPs. 
Immunisation results 
Intranasal immunisation successfully elicited 
significantly higher IgG2a levels than in s.c. 
route. This predominant Th1 response indicates 
that intranasal immunisation is a suitable route 
for a cell-mediated immune response against 
TB. Mucosal stimulation was confirmed by 
increased sIgA levels in the lungs.  
Formulation  
CS/ALG 
(w:w) 
Mean particle 
size (µm) 
Span ZP (mV)  
BCG Pasteur 
(CFUs/mL) 
E.E. (%)  
M13 1:0.8 11.8 1.6 +12.1 ± 0.9 Empty -- 
L14 1:1 10.0 2.1 -23.7 ± 0.2 Empty -- 
BCG/L14 1:1 22.2 6.5 -16.4 ± 2.1 1.7E+06 64% 
BCG/CS -- -- -- +90.6 ± 3.5 1.7E+06 -- 
BCG -- -- -- -23.1 ± 11.5 1.7E+06 -- 
Span = [d (0.9) - d (0.1)] / d (0.5) ; E.E. - Encapsulation Efficiency 
  
Figure 4. Secretory IgA (sIgA) 
levels of lungs homogenates of 
immunised mice 
Figure 3. Serum anti-M.tb specific IgG (I), IgG1 
(II) and IgG2a (III) profiles of mice immunised by 
i.n. route with  chitosan suspended BCG, 
compared to plain BCG and s.c. route. 
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